Important note

This AI stock analysis for Humana is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Humana - AI Stock Analysis

Analysis generated October 2, 2024

Humana Inc. is a prominent player in the health insurance industry, offering a variety of health, wellness, and insurance services. Established in 1961, Humana has grown significantly over the decades, focusing on providing Medicare Advantage health plans to individuals, as well as employer group insurance plans. With a market presence spanning multiple states in the U.S., Humana continues to be a vital player in the healthcare industry. Despite facing various market challenges, the company has shown resilience through its comprehensive health service offerings and strategic partnerships.

Fundamental Analysis

Revenue for the last quarter was $29.5 billion. This represents a decrease of 0.24% compared to the quarter before it, indicating some level of concern regarding short-term growth. However, compared to the same quarter last year, there is a notable increase of 10.44%, suggesting positive year-over-year growth. This discrepancy highlights potential seasonal factors or operational shifts impacting short-term performance.

Net income for the last quarter stood at $679 million, which marks a decrease of 8.37% compared to the previous quarter, and a significant decrease of 29.20% compared to the same quarter last year. The decline in net income is a critical metric, as it points to potential profitability issues and could reflect challenges in managing costs or changes in operational efficiency.

EBITDA for the last quarter was $1.35 billion, reflecting a slight decline of 0.51% compared to the previous quarter and a 2.73% decrease from the same quarter last year. EBITDA is a critical measure of operational performance, and these decreases, although relatively minor, are not ideal.

The current P/E ratio is 22.32, which appears to be within a normal range, neither particularly high nor low. This suggests that the market views Humana's stock price as fairly valued given its earnings.

Technical Analysis

Today’s stock price is $279.45, which represents a significant decrease of 20.94% compared to a month ago and a sharp decline of 42.23% compared to a year ago. The trend is bearish, indicating potential investor concerns or broader market weaknesses impacting Humana's stock.

The current SMA10 is $307.82, lower than the previous SMA10 of $310.83. This suggests a potential downward trend in price movements. Furthermore, the RSI is at 75.5, indicating a potentially overbought condition, which often precedes a price drop.

Alternative Data Analysis

Analyzing job postings and employee sentiment, Humana has 677 open positions according to the most popular job boards. This number is down by 6% in the last couple of months, possibly indicating efforts to improve margins or cut costs, which is not typically a sign of a growing company.

The business outlook among employees at Humana is neutral. This sentiment metric is vital as it provides insights into employee morale and outlook, which can impact overall company performance.

Humana has an estimated 5.9 million visitors to their webpage, with no meaningful increase or decrease in the last couple of months. Mobile app downloads are steady at around 520 users per day. While stable customer acquisition and engagement metrics are positive, they do not signal significant growth momentum.

The company's social media presence also remains stagnant, with 21,000 followers on Instagram and 44,000 on Twitter, showing no notable change. This could imply a need for enhanced marketing or customer engagement strategies.

AltIndex’s AI score for Humana stands at 47, which is a hold signal. This score incorporates fundamental, technical, and alternative data analyses to provide an aggregated sentiment on the stock.

Conclusion and Recommendation

In conclusion, Humana presents a mixed bag of signals for potential investors. While the company exhibits solid year-over-year revenue growth, the declines in net income and EBITDA, coupled with a bearish technical trend, raise concerns. Moreover, the stable but unremarkable alternative data metrics further suggest that the company is in a phase of consolidation rather than robust growth. Given the AltIndex AI score of 47, a hold recommendation appears prudent at this juncture.

Potential investors should continue to monitor Humana's performance closely, particularly focusing on its efforts to improve profitability and market position. For existing shareholders, holding onto the stock may be sensible, while new investors might want to wait for clearer signals of a turnaround or growth acceleration before making a commitment.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.